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Endothelial cells (EC) are sentinels of cardiovascular health. Their function is reduced by the 
presence of cardiovascular risk factors, and is regained once pathological stimuli are removed. In 
this European Society for Cardiology Position Paper we describe endothelial dysfunction as a 
spectrum of phenotypic states and advocate further studies to determine the role of EC subtypes in 
cardiovascular disease. We conclude that there is no single ideal method for measurement of 
endothelial function. Techniques to measure coronary epicardial and microvascular function are 
well established but they are invasive, time-consuming and expensive. Flow-mediated dilatation 
(FMD) of the brachial arteries provides a non-invasive alternative but is technically challenging and 
requires extensive training and standardization. We therefore propose that a consensus 
methodology for FMD is universally adopted to minimize technical variation between studies, and 
that reference FMD values are established for different populations of healthy individuals and patient 
groups. Newer techniques to measure endothelial function that are relatively easy to perform, such 
as finger plethysmography and the retinal flicker test, have the potential for increased clinical use 
provided a consensus is achieved on the measurement protocol used. We recommend further 
clinical studies to establish reference values for these techniques and to assess their ability to 
improve cardiovascular risk stratification. We advocate future studies to determine whether 
integration of endothelial function measurements with patient-specific epigenetic data and other 
biomarkers can enhance the stratification of patients for differential diagnosis, disease progression 
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1. DEFINING ENDOTHELIAL FUNCTION AND DYSFUNCTION. 
1.1 What is endothelial dysfunction? 
The vascular endothelium acts a semipermeable barrier to regulate an exchange of fluids, nutrients, 
and metabolites, and is critical to haemostasis and vascular health. In healthy arteries, endothelial 
cells (ECs) exist in a quiescent state that is maintained by laminar blood 1, 2, and by circulating 
cytoprotective factors such as high density lipoprotein (HDL)3. However, several stimuli including 
chronic disease states4, metabolic conditions (e.g. type 2 diabetes mellitus (T2DM), obesity, 
dyslipidemia), smoking5 and disturbed blood flow6-8 interrupt the quiescent phenotype and drive EC 
dysfunction9, 10 In 1998, Hunt and Jurd defined dysfunctional ECs by 5 key characteristic 
mechanisms: 1) loss of vascular integrity, 2) increased expression of adhesion molecules, 3) pro-
thrombotic phenotype, 4) production of cytokines and 5) up-regulation of human leukocyte antigen 
molecules10. It is now known that EC dysfunction is not a single pathological state but instead 
represents a spectrum of phenotypes associated with pathophysiologically heterogenous 
alterations in vascular tone, permeability, inflammation and de-differentiation, leading to the loss of 
homeostatic functions of endothelium (Figure 1). Indeed, recent single cell RNA sequencing studies 
have revealed multiple distinct EC subtypes for instance with aneurysms and atherosclerosis, thus 
emphasising the heterogeneity of ECs in diseased tissues11-14 Aside from tissue-resident 
endothelium, EC dysfunction also involves changes in circulating endothelial colony forming cells 
(ECFCs) and endothelial-derived microvesicles (EMVs) that have major roles in cardiovascular 
health and disease. 
 
1.2 Vascular tone, nitric oxide and superoxide anion. 
For their discovery of nitric oxide (NO) as a signalling molecule in the cardiovascular system, Ferid 
Murad, Robert Furchgott and Louis Ignarro earned the Nobel Prize for medicine in 1998. NO, a 
gaseous mediator produced by ECs, is generated from the nitrogen atom of L-arginine and O215, 
and catalysed by endothelial nitric oxide synthase (eNOS)16. While primarily defined through its 
regulation of vasorelaxation and vascular tone, NO exerts several atheroprotective effects including 
protection against oxidative stress, platelet activation and aggregation, inflammation and smooth 
muscle cell (SMC) proliferation17. However, the bioavailability of NO is reduced by numerous 
cardiovascular risk factors18. eNOS dimer is the main contributor to homeostatic NO in healthy cells. 
In pathology, when important co-factors such as tetrahydrobiopterin (BH4) are depleted, eNOS 
becomes uncoupled and it’s monomers contribute to reactive oxygen species (ROS) production19 
which is a driver of EC dysfunction. Reduced bioavailability of NO can also be due to oxidative 
inactivation. Indeed, loss of BH4 is often linked to vascular oxidative stress, characteristic for all 
major clinical risk factors for atherosclerosis, including diabetes, hypertension, 
hypercholesterolemia and smoking20. In human vasculature, endothelial and smooth muscle 
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NADPH oxidases contribute to superoxide anion production21-23. Rapid scavenging of NO by 
superoxide with generation of strongly prooxidant peroxynitrite (ONOO-) remains the principal 
mechanism of endothelial dysfunction in wide range of clinical conditions. ONOO- is in turn able to 
oxidize BH4 to BH2 contributing to eNOS uncoupling24. In some cases, eNOS substrate L-arginine 
or co-factor NADPH bioavailability may be limited, or eNOS expression inhibited by epigenetic 
modifications, including miRNA.  The relative importance of these distinct mechanisms of loss of 
NO bioavailability may differ in individual patients leading to the need for precision medicine 
approaches. These could be achieved by biomarker screening such as for example plasma BH4, 
miRNA, L-Arginine allowing for targeted approach to pathology underlying the dysfunction  
 
1.3 Vascular permeability and inflammation. 
It is well recognised that pro-atherogenic stimuli and cardiovascular risk factors, including diabetes, 
obesity and smoking cause functional and structural changes in the permeability properties of the 
endothelium. These alterations are characterised by a rise in the movement of plasma across the 
vessel wall and into the surrounding tissues, comprehensively reviewed elsewhere25. Numerous 
studies show that endothelial permeability, inflammation and atherosclerosis are inextricably linked. 
Interleukin (IL)-1 is a cytokine that is activated by the NLRP3 inflammasome, a master regulator 
involved in innate immunity. Thus, as a result of NLRP3 inflammasome/IL1 activation by 
cholesterol crystals, lipids and triglyceride-rich lipoproteins, pathogen-associated molecular 
patterns and disturbed blood flow26-33,  ECs will be activated and express adhesion molecules (e.g. 
vascular adhesion molecule-1, intercellular cell adhesion molecule-1, E-selectin) to drive vascular 
inflammation and atherosclerosis initiation and progression. Mendelian Randomization (MR) studies 
have now shown strong links between specific inflammatory proteins and lipid metabolism in 
patients with an inflammatory status, providing the impetus to develop novel systemic and vascular 
immunomodulatory approaches to address the public health challenge of cardiovascular disease 
(CVD). Thus, genetic screens linking metabolic and plasma proteomic profiles with causal effects, 
are becoming an attractive approach in the cardiovascular precision medicine arena34, 35 and may 
provide both novel targets and/or an improved prognostic tool for stroke, ischemic heart disease 
and T2DM36. 
 
1.4 Phenotypic plasticity. 
The full details of EC plasticity are outside the scope of this ESC Position Paper but have been 
extensively reviewed elsewhere37-39. It is now established that endothelial-to-mesenchymal 
transition (EndMT), a process characterised by loss of EC markers, gain of mesenchymal markers, 
activation and delamination, is of particular relevance in atherosclerosis39. Endothelial-lineage 
tracing studies from the Simons laboratory revealed that ECs activated in response to TGFβ 
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signaling undergo EndMT leading to migration, dedifferentiation and contribution to plaque 
formation and progression40. Kovacic and his team used endothelial-specific lineage-tracking, to 
show that EndMT-derived fibroblast-like cells are present in atherosclerotic lesions, and coexpress 
endothelial and fibroblast/mesenchymal proteins, a recognised hallmark of EndMT41. Further 
studies have revealed that EndMT is driven by disturbed flow, oxidative stress and hypoxia 41-43; all 
of which trigger progression of atherosclerosis. However, the contribution of EndMT-derived cells 
to plaque development is an area of ongoing investigation. 
 
1.5 Organ-specific endothelial cell specialization. 
ECs are specialized in different vascular beds, such as the unique vasculature of the kidneys or the 
blood-brain barrier. Specific subtypes of endothelial cells have also been found in adipose tissue, 
gut and other tissues, and multiple distinct EC subtypes have been revealed by single cell 
sequencing in aorta13 and atherosclerotic plaques11. Unravelling the as yet unknown molecular 
pathways that specify and sustain each organ functional and structural diversity will set the stage 
for deciphering the pathogenesis of several disorders, allowing future attempts at reversal of 
endothelial dysfunction and improved patient outcome. At the same time, while molecular 
mechanisms appear to differ between different vascular beds, clinically measured vascular 
dysfunction can correlate between different arterial beds44 as well as between arterial and venous 
endothelium45 suggesting that endothelial dysfunction can be systemic. 
 
1.6 ECFCs and EMVs. 
ECFCs comprise a heterogenous population of cells that have distinct roles in angiogenesis and 
vascular repair. A number of reports suggest their numbers increase with disease activity in patients 
with vasculitis and other vascular disorders and that progenitor repair cells become exhausted in 
disease (Figure 2)46, 47. ECFCs can be cultured from patients and analysed for pathophysiological 
properties and epigenetic markers and this approach has the potential to inform precision 
cardiovascular medicine. EMVs are extracellular vesicles of 0.2-5m diameter that are produced by 
ECs in response to a variety of stimuli48. They can exert paracrine and autocrine actions on vascular 
cells with the potential to modulate key intracellular signalling pathways, promoting disease 
progression via transfer of a range of bioactive molecules (growth factors, proteases and 
microRNAs) to adjacent cells (Figure 2).  
 
1.7 Summary. 
Although a conventional definition of endothelial dysfunction has focused on NO dysregulation and 
an altered redox status49, EC dysfunction involves a range of plastic phenotypic states with 
inflammation and enhanced permeability. Indeed, it is clear from recent studies that ECs assume 
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multiple diverse phenotypes associated with various disease states including hypertension, 
atherosclerosis and the development of heart failure (Figure 1). This is exemplified by fate mapping 
and single cell RNAseq studies that have revealed multiple EC phenotypes associated with health 
and disease11-14 and recent insights into the function of ECFCs and EMVs in CVD (Figure 2). 
Together, these findings have led to growing interest in assessing endothelial function by a range 
of traditional and novel methods, discussed below, to inform about individual patient risk, to guide 
best therapy, clinical management and ultimately to establish whether it is feasible to target 
endothelial dysfunction and attenuate CVD progression50, 51. This could enhance the field in 
applying novel endothelial function tests and endothelial damage biomarkers to innovate a more 
personalised approach to cardiovascular medicine.  
 
2. MEASURING ENDOTHELIAL FUNCTION 
The ideal method to assess endothelial function should be non-invasive, easy to use, prospectively 
validated in different cohorts and ethnic groups, with an incremental value over and above standard, 
clinically established risk markers, cost-effective, measured according to methodological consensus 
and providing reference values as a basis for treatment52, 53. Both invasive and non-invasive 
methods to assess vascular endothelial function have their advantages and disadvantages (Table 
1). The basic principle of these methods, however, is similar. Healthy arteries such as the coronary 
or brachial arteries dilate in response to the increased shear stress associated with reactive 
hyperaemia (flow-mediated vasodilatation) or after pharmacological stimuli including intra-arterial 
infusion of endothelium-dependent vasodilators including acetylcholine (Ach), bradykinin or 
serotonin, via release of NO and/or other endothelium-derived vasoactive substances54. In disease 
states, such endothelium-dependent dilatation may be reduced or absent. It should be noted that 
vascular responses are not only determined by the functional status of the vasculature at the point 
of measurement, but also by the structural condition of the resistance arteries in the 
microvasculature. Furthermore, vascular dysfunction can also be endothelium-independent function 
via alterations in vascular structure and SMC function rather than changes in EC. To differentiate 
endothelium-dependent from endothelium-independent responses, exogenous NO donors (e.g. 
glycerol-trinitrate) or vasodilators such as adenosine, acting directly on the vascular smooth muscle, 
can be applied. This section focuses on methods which are already established and which have the 
perspective to be implemented in clinical practice. Research methods such as infusion of NO 
synthase inhibitors such as L-NMMA are out of the scope of this paper and will not be discussed in 
detail. 
 
2.1 Coronary circulation. 
2.1.1 Coronary epicardial function 
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To assess coronary endothelial function, a “functional” test is performed to measure epicardial, as 
well as resistance vessel endothelial function. Although these methods are limited by their invasive 
nature, their advantage is to measure EC function directly in this clinically important vascular bed. 
To image vasomotor responses of epicardial coronary arteries, quantitative coronary angiography 
(QCA) or intravascular ultrasound (IVUS) is used to measure changes in vessel diameters and 
cross-sectional areas in response to endothelium-dependent pharmacological interventions. 
Vessels and segments with an intact endothelium vasodilate in response to Ach and other 
endothelial-stimulating substances, whereas vessels and segments with dysfunctional or disrupted 
endothelium will respond exhibit reduced vasodilatation or vasoconstriction due to a direct activation 
of muscarinic receptors on vascular SMCs55, 56. The observation of endothelium-dependent flow-
mediated dilatation in the coronary epicardial vessels and its impairment in atherosclerosis57, 58 has 
provided the rationale to study similar responses in the peripheral vasculature later (see below). 
Finally, it should be mentioned that this technique should be used with caution, as serious (although 
rare) side effects may occur that carry risks for the patient, such as severe coronary vasoconstriction 
or the induction of arrhythmias. 
 
2.1.2 Coronary microvascular function 
Changes in coronary (or myocardial) blood flow (CBF) can be used as a surrogate parameter for 
microvascular function59. Coronary flow reserve (CFR) is the ratio of maximal CBF during maximal 
coronary hyperemia with provocative stimuli (including adenosine infusion, pacing or exercise), 
divided by the resting CBF. This maximal blood flow response (CFR) is both endothelium and non-
endothelium dependent and a CFR below 2.0 is considered abnormal60. Unfortunately, there are no 
invasive methods for measuring CBF directly in clinical practice. Instead, wire-based Doppler flow 
velocity or thermodilution techniques are used as surrogates but these are technically challenging, 
require additional hardware and can lack reproducibility and as such have not entered routine 
clinical practice. Furthermore, variability in baseline CBF measurements can make CFR difficult to 
interpret. Physiological indices such as index of myocardial resistance (IMR) or hyperaemic 
/baseline microvascular resistance (HMR /BMR) may gain prominence in assessing coronary 
microvascular function, but these require accurate CBF measurement and currently also rely on 
thermodilution- and Doppler-based surrogate flow measures respectively. There is a need for an 
accurate, clinically acceptable method to measure volumetric CBF. To measure endothelium-
dependent microvascular function, the percentage increase in CBF in response to endothelium-
dependent vasodilators (commonly Ach), infused at increasing concentrations, is analyzed. To 
counteract the invasive nature of the above-mentioned tests – non-invasive functional tests to 
assess the coronary microvasculature have been developed, which include positron emission 
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tomography61, myocardial perfusion imaging62, blood oxygen level-dependent (BOLD) MRI63 and 
echocardiography62. 
 
2.2 Peripheral techniques to assess endothelial function 
The aforementioned techniques are suited for patients requiring a coronary angiogram for other 
clinical indications. However, to assess vascular function in the asymptomatic patient, performing 
an invasive functional coronary angiogram is not indicated or feasible. Therefore, non- or less 
invasive surrogate techniques to assess macrovascular as well as microvascular endothelial 
function have been developed. Although these do not measure vascular function in the coronary 
circulation directly, they have been shown to correlate with its invasive counterparts64-66. Whereas 
all of these techniques assess the generalised function of the vasculature, certain phenomena 
cannot be explained by systemic endothelial dysfunction, e.g. local vascular dysregulation observed 
at branch points related to disturbed shear stress67-69.  
 
2.2.1 Plethysmography of the Forearm Circulation 
Although still limited by its semi-invasive nature (arterial puncture), in this technique, changes in 
forearm blood flow are measured by plethysmography in both arms before and after infusion of 
vasoactive substances into a cannulated brachial artery70. The main advantage is that vasoactive 
molecules, hormones or drugs can be infused, thus quantifying both endothelium-dependent and 
endothelium-independent vasodilation in a dose-dependent manner. The infused dosages required 
have limited systemic effects, allowing the contralateral limb to serve as an internal control. The 
results are expressed as the ratio of the changes in flow, measured in both arms and are 
reproducible71.  
 
2.2.2 Flow-mediated vasodilation of brachial artery 
Due to its non-invasive approach, flow-mediated vasodilatation (FMD) of the brachial artery has 
become the most widely used technique to evaluate endothelial function. The technique measures 
the ability of larger conduit arteries to dilate in response to reactive hyperaemia (flow-mediated) 
after a 5-minute suprasystolic occlusion of the brachial artery with a blood pressure cuff. The 
resultant reactive hyperemia causes an increase in endothelial shear stress in upstream artery, 
which in turn stimulates release of NO. Celermajer, Deanfield and colleagues were the first to 
evaluate this response in vivo by measuring the respective diameter changes of the brachial artery 
by ultrasound72, later demonstrated to be mainly NO-dependent73-75, although other vasodilator 
pathways may contribute as well76. Importantly, peripheral endothelial function as assessed by FMD 
correlates with coronary artery endothelial function64, 66. Although the principle of FMD appears 
simple, its application is technically challenging and requires extensive training and 
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standardization77-80. Study preparation, image acquisition and site selection, sphygmomanometer 
probe position, cuff occlusion time, the accurate use of edge-detection software as well as the 
correct characterization of the FMD response are crucial, as recently outlined in dedicated 
guidelines77, 80-82. These guidelines are of critical importance, as they emphasize the need to 
standardize protocols and technology to improve reproducibility and data interpretation of FMD83. 
The semi-automatic measurement of brachial FMD with self-adjusting ultrasound probes and 
automatic edge detection of the arterial wall will likely facilitate the usage in clinical practice and has 
already established reference values for a Japanese population84. While FMD assesses conduit 
artery vascular function, the stimulus for FMD itself (reactive hyperaemia flow and the induced shear 
stress on the endothelium) might be an important parameter of peripheral microvascular function 
because reactive hyperaemia is highly dependent on maximal forearm resistance85, 86. Notably, both 
hyperaemia-induced shear stress and velocity changes (measured by calculation of the velocity-
time integral, adjusted for heart rate) have shown even stronger correlations with the presence of 
cardiovascular risk factors than FMD87 and also predict cardiovascular outcomes88, 89. Interestingly, 
recent multi-centre studies demonstrated that simple baseline brachial artery diameter readings 
correlate with clinical outcomes, nearly as well as FMD itself90, 91. This finding reveals a significant 
limitation of the in vivo assessment of endothelium-dependent vasodilation. In contrast to the ex 
vivo situation, the baseline arterial tone cannot be standardised. Therefore, the amount of additional 
dilatation depends on the initial diameter of the vessel and could paradoxically show poor FMD in a 
situation of initial vasodilation due to a well-functioning endothelium (e.g. in pregnancy or in 
hyperthermia). These influencing factors strongly warrant a strict standardization of the 
measurement environment (e.g. room temperature, resting phase) and the consideration of clinical 
conditions that may influence baseline diameter and vasodilation80. 
 
2.2.3 Finger plethysmography  
Endothelial function measurement using peripheral arterial tonometry (PAT) was first used by 
Bonetti et al to identify patients with early coronary atherosclerosis. A proprietary device has been 
developed to quantify observer-independent pulsatile arterial volume changes by finger 
plethysmography92, 93. Beat-to-beat plethysmographic recordings of the finger arterial pulse wave 
amplitude with pneumatic probes are captured93. In principle, an increase in arterial blood volume 
in the fingertip causes an increase in pulsatile arterial column changes, thus increasing the 
measured signal. Similar to the assessment of endothelial function with the FMD technique, a 
pressure cuff is placed on the arm and after obtaining baseline blood volume changes, the blood 
pressure cuff is inflated above systolic pressure and deflated after 5 minutes to induce reactive 
hyperaemia in one arm. A major advantage of the system is that the contralateral arm serves as its 
internal control that can be used to correct for any systemic drift in vascular tone during the test and 
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an index between the two arms is calculated to adjust for any such drift. This index is a validated 
marker for endothelial function; however, augmentation of the pulse amplitude after reactive 
hyperaemia is a complex response to ischemia. It reflects changes in flow, as well as in digital micro 
vessel dilatation and is only partly dependent on NO94. Further studies demonstrated that 
impairment in peripheral finger EC function is correlated with coronary microvascular function in 
patients with early atherosclerosis65 and predicts cardiovascular events95. In two large cross-
sectional studies [in over 1900 patients in the Framingham cohort96, 97 and over 5000 individuals in 
the Gutenberg Heart Study98 digital vascular dysfunction was associated with traditional and 
metabolic cardiovascular risk factors but not or only modestly with FMD, thus likely measuring 
different aspects of vascular biology. A disadvantage of the proprietary device is the high cost per 
measurement system, the lack of reusability and the limited parameters offered for further analysis.   
 
2.2.4 Retinal endothelial function 
For the assessment of the retinal endothelial function, several types of provocation are possible 
including flicker light99. The vessel’s reactions are at least partially dependent on NO release and 
partially attributed to neurovascular coupling99, 100. Solid data for patient groups are still lacking, 
partly due to variation in the flicker response between individuals due to variation in the baseline 
diameter of retinal vessels101, 102. Moreover, a consensus on the protocol used in order to achieve a 
better comparability of study results, is still lacking103. These concerns should be addressed, as 
should the study of larger and more representative groups of individuals and patient cohorts before 
recommendations for wider use in clinical practice and prevention can be made. Nevertheless, 
flicker-induced dilatation of retinal vessels has been shown to depend on age and gender in 
individuals free of major risk factor burden and prevalent disease104. It is impaired in patients with 
obesity103, 105 renal disease106 and diabetes compared to age-matched healthy controls107, 108. In 
hypertension, flicker-induced dilation is also reduced109, 110 and it is associated with an increase of 
inflammatory biomarkers109. 
 
2.3 Summary. There is not an ideal method for empirical measurement of endothelial function. 
Techniques to measure coronary epicardial and microvascular function are well established but they 
are invasive, time-consuming and expensive. Several techniques are available for measurement of 
reactive hyperaemia in peripheral arteries, which provide a less-invasive assessment of endothelial 
function. FMD of the brachial arteries is the most commonly used, but it is technically demanding 
and requires a high degree of training and experience to ensure accurate measurements, but semi-
automatic, easier to use tools are approaching.  may be overcome by techniques, such as finger 
plethysmography, that are easier to use; however, the utility of newer methods is restricted because 
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of a lack of methodological consensus, lack of reference values in healthy individuals and limited 
validation in large clinical trials. 
 
3 ENDOTHELIAL DYSFUNCTION AND ARTERIAL DISEASE  
3.1 Arterial hypertension. 
Hypertensive patients have impaired endothelial-dependent vasodilatation both in coronary 
arteries111 and in the forearm112 (Supplementary Table 1), and data from the Framingham offspring 
cohort suggest that the degree of endothelial dysfunction is positively associated with the severity 
of hypertension113. However, in a cohort of 3500 ethnically diverse persons from the Multi-ethnic 
Study of Atherosclerosis (MESA), until now the largest clinical study in the field, impaired FMD was 
not a significant independent predictor of hypertension development, after adjustment for co-
variables114. A possible explanation for these seemingly disparate observations is that the 
interaction between EC function and hypertension may vary between populations. This underscores 
the importance of developing reference FMD values for different populations. It is also plausible that 
stratification of patients (e.g. using omics/epigenetics data or via analysis of ECFCs or EMVs) may 
identify sub-groups where FMD values are more accurately coupled to disease risk115 (see Section 
4). 
 
3.2  Diabetes. 
Diabetes is associated with a two- to four-fold increased risk of CVD, mainly attributable to 
hyperglycaemia, dyslipidaemia and oxidative stress116. Endothelium-dependent vasodilation in 
peripheral117  and coronary118 arteries  of patients with Type 2 DM is blunted (Supplementary Table 
2), principally due to loss or reduction of NO119. The relationship between insulin resistance and 
endothelial dysfunction is complex and endothelial dysfunction probably precedes the onset of . 
Indeed, polymorphisms of eNOS are multivariable predictors of incidence of 120. Several 
mechanisms of endothelial dysfunction are proposed in the setting of DM including: increased 
oxidative stress121, uncoupling of eNOS122, pro-inflammatory activation of EC123, mitochondrial 
dysfunction124, impaired endothelial repair potential125, and increased permeability126, 127. Although 
the role of endothelial dysfunction in pathogenesis of micro- and macrovascular complications is 
well documented, endothelium-dependent peripheral vascular tests do not appear to improve risk 
stratification in patients with T2DM 128, 129. However, given the range of endothelial mediators and 
their multiple mechanisms of action which contribute to endothelial abnormalities, FMD may not 
represent the most appropriate measure of the early signs of endothelial metabolic disturbances.   
 
3.3 Coronary artery disease (CAD). 
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Multiple studies have addressed the hypothesis that endothelial dysfunction may improve risk 
stratification above well-established risk scores/factors for CAD (Supplementary Table 3), thereby 
offering the possibility of early and personalised therapy. Consistent with this concept, peripheral 
macrovascular endothelial dysfunction, estimated by FMD90, 130, 131 or finger plethysmography132 was 
demonstrated to independently predict major adverse cardiac events (MACE) in several populations 
at risk for CAD. Moreover, a recent systematic review and meta-analysis including 35 FMD studies 
and 6 PAT studies found that these tests provided a similar prognostic value in predicting 
cardiovascular events133. In contrast, three large prevention trials failed to confirm the predictive 
value of FMD (macrovascular endothelial dysfunction), but instead found that markers of 
microvascular endothelial dysfunction (hyperaemic velocity in FATE88 and invasive forearm 
technique with Ach in PIVUS134 were associated with increased MACE risk and improved risk 
discrimination substantially, independent of established risk scores. The reason why FMD had 
prognostic value in some, but not in all populations is uncertain, but could be related to differences 
in the age and physical activity of the populations that were studied88, 130, 131, 135. It is also plausible 
that FMD may predict cardiovascular risk in a proportion of patients but not in others. It follows that 
integrating FMD measurements with patient-specific genetic and epigenetic characteristics may 
provide a personalised approach for predicting cardiovascular risk. 
 
3.3.1 Ischemia and no obstructive coronary artery disease. 
A substantial proportion of patients, especially women with anginal symptoms and myocardial 
ischemia, have an absence of flow-limiting obstruction in the epicardial arteries at coronary 
angiography136, 137. This syndrome has been increasingly recognised and recently termed as 
Ischemia and No Obstructive Coronary Artery disease (INOCA) or Angina and No Obstructive 
Coronary Artery (ANOCA) disease. The pathophysiology of INOCA includes dysfunctionality in 
coronary macrovascular (i.e. epicardial coronary arteries) and/or microvascular compartment (i.e. 
small intramural pre-arteriolar coronary arteries). Bairey Merz et al have identified a series of 
investigations to define INOCA including measurement of endothelial dysfunction138.  A panel of 
invasive measurements includes coronary vasomotor testing with intracoronary adenosine (to 
measure CFR, that estimates endothelium-independent microvascular function), Ach (to measure 
endothelium-dependent coronary vasoreactivity) and nitroglycerin (to measure endothelium-
independent macrovascular function; Supplementary Table 4). Coronary endothelial dysfunction is 
defined as microvascular, if the change in coronary blood flow in response to Ach is <50%, and 
macrovascular in case of Ach-induced epicardial vasoconstriction139. The results of such testing 
should help to guide therapy in individual patients e.g. to determine whether microvascular 




3.3.2 Chronic coronary syndromes and progression to plaque instability. 
Coronary macro- and microvascular endothelial dysfunction can predict acute vascular events 
independently of conventional CAD risk factors and angiographically-proven coronary 
atherosclerosis. For example, although patients with high-risk coronary anatomy (left main stenosis 
and three vessels with CAD) were excluded140, the detection of microvascular endothelial 
dysfunction was associated with a 2.4-fold increase in event rates, while the detection of epicardial 
endothelial dysfunction was associated with a 1.4-fold elevation of event rates (independently from 
other risk factors and presence of CAD). These associations point to the importance of coronary 
endothelial dysfunction for the transition from a stable to unstable form of atherosclerotic disease. 
Furthermore, peripheral endothelial dysfunction (brachial plethysmography) distinguished subjects 
at a higher risk for cardiac and total vascular events  in populations with documented CAD, 
highlighting the importance of systemic endothelial changes in plaque progression141. 
Atherosclerosis is a focal disease142 and it is therefore noteworthy that coronary segments with a 
higher degree of endothelial dysfunction are associated with more vulnerable plaque containing a 
necrotic core (evaluated by IVUS69) suggesting that localised EC dysfunction may predict focal 
progression into culprit lesions and acute coronary syndromes.  
 
3.3.3 Acute coronary syndromes (STEMI, NSTEMI, MINOCA). 
The pathophysiological mechanism underlying type 2 myocardial infarction (MI) is an acute 
mismatch between oxygen supply and demand, leading to acute ischaemic myocardial injury143. 
Mechanisms include coronary artery spasm and/or coronary microvascular dysfunction143. During 
the course of atherosclerosis, local inflammation and oxidative stress affect endothelial function and 
promote plaque vulnerability, with consequent platelet adhesion, vasospasm, stasis and coronary 
thrombosis, leading to acute coronary syndrome144. Importantly, endothelial dysfunction is present 
not only at the site of the culprit lesion, but also in distant, non-culprit coronary arteries, even with 
normal angiographic appearance145. Aggravation also occurs in peripheral endothelial dysfunction 
after acute coronary syndrome and its normalization predicts a lower risk of future events146. 
Relatively few studies have correlated endothelial dysfunction with MI with Non-Obstructive 
Coronary Arteries (MINOCA) which arises, due to either atherosclerotic plaque disruption and 
coronary thrombosis (i.e. type 1 MI), or coronary vasospasm (i.e. type 2 MI), along with other 
possible causes. In the Stockholm Myocardial Infarction with Normal Coronaries (SMINC) study, 
peripheral microvascular endothelial function was normal in MINOCA patients compared to 
controls147. Overall, although microvascular dysfunction is presumed to be a causal component in 
ACS, both in type 1 and even more frequently in type 2 MI, there are uncertainties whether it is a 




3.4 Summary. There is a wealth of evidence that endothelial dysfunction is a key player in the 
initiation of atherosclerosis and plaque progression. Endothelial dysfunction in coronary 
macrovascular or microvascular compartments may predict and/or drive disease progression into 
culprit lesions, acute coronary syndromes and INOCA. Consistent with this, endothelial dysfunction 
has been demonstrated in asymptomatic individuals with risk factors for atherosclerosis (i.e. before 
clinical manifestation of the diseases) and, large clinical trials demonstrated that microvascular 
endothelial dysfunction can independently predict MACE in populations at risk for CAD. However, 
there are several examples in the literature where the correlation between EC dysfunction and 
disease risk varies considerably between studies. This can be partly attributed to technical 
considerations, thereby underlying the importance of methodological consistency, but may also be 
related to biological factors that vary between individuals and/or between populations therefore 
requiring a precision medicine approach. 
 
4 ENDOTHELIAL FUNCTION IN PRECISION MEDICINE   
4.1 Can endothelial function measurements be used to stratify patients for therapy? 
Results from most clinical trials have documented that despite the successful control of 
cardiovascular risk factors achieved with cardiovascular drugs, the impact on cardiovascular 
morbidity and mortality reduction is limited (around 20-45%). Consequently, tools that might enable 
identification of those patients who develop future events, despite optimal treatment are urgently 
needed. Several findings support the possibility that endothelial function could be used to identify 
patients that remain at high cardiovascular risk. For example, among 251 Japanese men with newly 
diagnosed stable CAD and concurrent impaired brachial artery FMD, those whose endothelial 
function did not improve after six months of optimised pharmacological treatment showed a 
significant higher event rate of cardiovascular events (26%) in the 31 months follow-up compared 
to those with improved endothelial function (10%)148. On the other hand, EC function can also 
identify patients with favourable responses to lifestyle changes, such as increased exercise, or 
pharmacological interventions. For example, moderate aerobic physical exercise can improve 
endothelium-dependent vasodilation, not only in healthy middle-aged men149, but also in patients 
with arterial hypertension150, CAD151 and chronic heart failure152. Endothelial function has also been 
improved by weight reduction either by diet153, 154 or bariatric surgery155, dietary interventions with 
foods rich in polyphenols (fruits, green tea and cocoa) 156, 157 as well as smoking cessation158. 
Beyond lifestyle interventions, the first finding that EC function measurements can be used to 
monitor pharmacological responses was obtained from controlled studies with statins159, 160. The 
mechanism is likely related to the documented anti-inflammatory and antioxidant properties of 
statins that result in improved availability of vascular NO161. Endothelial function can also be used 
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to monitor responses to other drugs with an effect on cardiovascular risk factors162 and some 
diabetes modulating drugs like metformin163 or glitazones163-165. 
 
4.2 Integrating endothelial functional measurements with biomarkers of vascular 
function. 
Genetic and epigenetic differences contribute to variation in endothelial function both in healthy 
individuals and in patients with CVD. Therefore, the ability to delineate patients at high 
cardiovascular risk and identify responders and non-responders to therapy can potentially be 
enhanced by integrating endothelial function measurements with genomic and epigenomic 
datasets. Non-coding RNAs are epigenetic markers of potential clinical use due to their high plasma 
stability and advances in experimental techniques used in their assessment. For example, the 
detection of specific circular RNAs and microRNAs in plasma has been linked to CAD and ACS 166 
and Sapp et al found that alterations in miR-126-5p correlated with endothelial function in response 
to exercise in healthy individuals167. There may also be value in quantitation of classical markers 
such as sICAM, sVCAM, IL-6, IL-8, IL-12, hsCRP and NO for integration with endothelial function 
assessment. There is also considerable interest in using circulating EMVs and ECFCs as a 
surrogate of endothelial health168. For example, anti-inflammatory treatment of patients with 
systemic lupus erythematosus simultaneously improved endothelial function and reduced EMV 
levels169 suggesting that EMV levels may report on vascular function. Of particular note, a recent 
study from Zacharia et al found that endothelial function correlated with circulating microvesicles in 
patients with ACS170. Moreover, studies of circulating ECFCs revealed that they correlate with 
enhanced microvascular function and repair in patients with acute MI171, 172.  These tools will 
significantly contribute to the field of precision medicine and identify patients at high risk of 
developing both micro- and macro-vascular complications173. 
 
4.3 Summary. 
Measurement of endothelial function can be used to monitor responses to lifestyle changes and 
pharmacological intervention, and can identify patients that remain at residual risk despite optimal 
therapy. The prognostic value of endothelial function measurement may be enhanced by integration 
with patient-specific information from omics and epigenetic studies and/or from analysis of the 
physiology of EMVs and ECFCs. These data may be combined through an algorithm that will 






1. Endothelial dysfunction does not describe a single endothelial phenotype but is 
characterised by a spectrum of phenotypic states, exemplified by multiple EC subsets and 
plasticity in atherosclerosis. The vascular biology community should delineate the 
contribution of various EC dysfunctional states to CVD and develop new technologies to 
measure pathogenic EC subsets in the clinic. 
 
2. FMD of the brachial arteries, the most commonly used measure of endothelial function, 
predicted cardiovascular risk in some large clinical trials but not others. Thus we 
recommend that a consensus, semi-automated methodology is adopted in future studies to 
minimize technical variation, and that reference FMD values are established for different 
populations. 
 
3. Newer techniques to measure endothelial dysfunction that are relatively easy to perform, 
such as finger plethysmography and the retinal flicker test, have the potential for increased 
clinical use provided a consensus is achieved on the measurement protocol used. In 
addition, larger clinical studies are needed to establish reference values and to assess their 
clinical utility.  
 
4. Future work should determine whether the prognostic value of endothelial function 
measurement can be enhanced by integration with patient-specific information from omics 
and epigenetic studies and/or from analysis of patient-derived EMVs and ECFCs.  
 
5. Assessment of coronary microvascular endothelial function would benefit from more 
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FIGURE LEGENDS  
 
Figure 1. Endothelial dysfunction describes multiple phenotypic states. 
Left Panel. In homeostatic conditions, the healthy endothelium regulates the physiological vascular 
function and structure through multiple beneficial effects of nitric oxide (NO), hydrogen sulphide 
(H2S) and carbon monoxide (CO), as detailed in the text. Right Panel. Dysfunctional endothelium is 
characterised by decreased production of NO and chronic increase of reactive oxygen species 
(ROS) able to overwhelm the intracellular antioxidant defence leading to onset and progression of 
atherosclerosis. eNOS: endothelial nitric oxide synthase; (EndMT): endothelial-mesenchymal 
transition; AA: amino acids. 
 
Figure 2. Schematic representation of the endothelial factors underlying cardiovascular risk.  
ECFCs: Endothelial colony forming cells, EMVs: endothelial microvesicles, EndMT: -endothelial-
mesenchymal transition, FMD: flow mediated dilatation, HSPG: heparan sulphate proteoglycans, 
IL: interleukin, MØ: macrophage, MR-proADM: Mid-regional pro-adrenomedullin, NO: nitric oxide, 
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